New treatments for multiple sclerosis.
作者信息
McDonald W I
出版信息
BMJ. 1995 Feb 11;310(6976):345-6. doi: 10.1136/bmj.310.6976.345.
Abstract
摘要
相似文献
1
New treatments for multiple sclerosis.
BMJ. 1995 Feb 11;310(6976):345-6. doi: 10.1136/bmj.310.6976.345.
2
Options for multiple sclerosis therapy.
JAMA. 1994 Nov 9;272(18):1393.
3
Disease modifying treatment in multiple sclerosis.多发性硬化症的疾病修饰治疗
J Neurol Neurosurg Psychiatry. 2001 Dec;71 Suppl 2(Suppl 2):ii20-1. doi: 10.1136/jnnp.71.suppl_2.ii20.
4
Guidance on new therapies in multiple sclerosis patients.
Lancet. 1996 Jul 13;348(9020):136. doi: 10.1016/s0140-6736(05)64657-0.
5
What is new in the treatment of multiple sclerosis?多发性硬化症治疗方面有哪些新进展？
Drugs. 2000 Mar;59(3):401-10. doi: 10.2165/00003495-200059030-00002.
6
[Logistics and description of treatment technology (the protocol for using disease modifying drugs--DMD)].[治疗技术的后勤保障与描述（使用疾病修正药物——DMD的方案）]
Zh Nevrol Psikhiatr Im S S Korsakova. 2011;111(2 Pt 2):93-8.
7
Newer versus older treatments for relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症的新型治疗方法与传统治疗方法对比
Drug Saf. 1996 Feb;14(2):121-30. doi: 10.2165/00002018-199614020-00006.
8
[A comparative analysis of rebif 22-mcg and copaxone efficacy in multiple sclerosis].
Zh Nevrol Psikhiatr Im S S Korsakova. 2006;Spec No 3:111-5.
9
Annualized relapse rate of first-line treatments for multiple sclerosis: a meta-analysis, including indirect comparisons versus fingolimod.一线多发性硬化治疗的年复发率：一项荟萃分析，包括与芬戈莫德的间接比较。
Curr Med Res Opin. 2012 May;28(5):767-80. doi: 10.1185/03007995.2012.681637. Epub 2012 Apr 24.
10
Interferons-beta versus glatiramer acetate for relapsing-remitting multiple sclerosis.β-干扰素与醋酸格拉替雷治疗复发缓解型多发性硬化症的比较
Cochrane Database Syst Rev. 2014 Jul 26(7):CD009333. doi: 10.1002/14651858.CD009333.pub2.
引用本文的文献
1
Anti-inflammatory therapy by ibudilast, a phosphodiesterase inhibitor, in demyelination of twitcher, a genetic demyelination model.磷酸二酯酶抑制剂异丁司特对遗传性脱髓鞘模型震颤小鼠脱髓鞘的抗炎治疗
J Neuroinflammation. 2005 Apr 6;2(1):10. doi: 10.1186/1742-2094-2-10.
2
Diminished production of type-I interferons and interleukin-2 in patients with multiple sclerosis.多发性硬化症患者中I型干扰素和白细胞介素-2的产生减少。
J Neurol Sci. 1997 Jul;149(1):87-93. doi: 10.1016/s0022-510x(97)05383-5.
3
A purchaser experience of managing new expensive drugs: interferon beta.一位购买者管理新型昂贵药物（干扰素β）的经历。
BMJ. 1996 Nov 9;313(7066):1195-6. doi: 10.1136/bmj.313.7066.1195.
4
Evaluating neurological outcome measures: the bare essentials.评估神经学结果指标：基本要素
J Neurol Neurosurg Psychiatry. 1996 Feb;60(2):127-30. doi: 10.1136/jnnp.60.2.127.
5
Telling your patient he/she has multiple sclerosis.告知你的患者他/她患有多发性硬化症。
Postgrad Med J. 1995 Aug;71(838):449-52. doi: 10.1136/pgmj.71.838.449.
本文引用的文献
1
Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group.干扰素β-1b对复发缓解型多发性硬化有效。II. 一项多中心、随机、双盲、安慰剂对照试验的MRI分析结果。英属哥伦比亚大学多发性硬化/MRI研究组和干扰素β多发性硬化研究组。
Neurology. 1993 Apr;43(4):662-7. doi: 10.1212/wnl.43.4.662.
2
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: statistical power of parallel-groups and crossover designs.磁共振成像在监测多发性硬化症患者治疗中的应用：平行组和交叉设计的统计功效
J Neurol Sci. 1994 Mar;122(1):6-14. doi: 10.1016/0022-510x(94)90045-0.
3
Preliminary evidence from magnetic resonance imaging for reduction in disease activity after lymphocyte depletion in multiple sclerosis.来自磁共振成像的初步证据表明，多发性硬化症患者淋巴细胞清除后疾病活动度降低。
Lancet. 1994 Jul 30;344(8918):298-301. doi: 10.1016/s0140-6736(94)91339-0.
4
Cladribine in treatment of chronic progressive multiple sclerosis.克拉屈滨治疗慢性进行性多发性硬化症。
Lancet. 1994 Jul 2;344(8914):9-13. doi: 10.1016/s0140-6736(94)91046-4.
Zotero 插件